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The \"Brazilian Guidelines on Antiplatelet Agents and Anticoagulants in Cardiology,\" published as supplement number three to the September 2013 edition of the Arquivos Brasileiros de Cardiologia \[Arq Bras Cardiol. 2013;101 (3Suppl.3):1-93\], was fixed as follows:

On page 17, Table 2, change the Class of recommendation of \"Exchange of heparins (UFH and enoxaparin)\" to III.

On page 31, Table 5, last line, consider correct the wording \"In situations of CHADSVasc zero or up to 1 (if it is only by the female sex), the non-use of oral anticoagulation (such as rivaroxaban) may be considered,\" Class of recommendation: II and Level of evidence: A.

On page 47, table 13, consider as correct the wording \"Indications\": \"Treatment of acute and chronic VTE at a dose of 15 mg twice a day in the first 21 days followed by 20 mg once a day for 3, 6, or 12 months or for a longer time at the physician\'s discretion.\"
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In \"I Brazilian Guidelines on Cardiovascular Prevention\", consider Izar MC as the correct form for the name of the author Maria Cristina de Oliveira Izar.
